Ultimately, robots can take blood samples, benefiting health care workers and patients.


A Rutgers-led group has produced a blood-sampling robot which performed as well or even better than individuals, according to the first human clinical trial of an automatic blood testing and drawing apparatus.


The system offers benefits and would enable health care professionals to spend more time treating patients in other settings and hospitals.

For the success rate was 97 percent.

The system involves an ultrasound robot which draws blood. A apparatus, which comprises a module which manages also a blood analyzer that was centrifuge-based along with samples, might be utilized in bedsides and in ambulances, emergency rooms, clinics, physicians’ offices and hospitals.


Venipuncture, that involves inserting a needle into a vein to receive a bloodstream sample or do IV treatment, is the planet’s most popular clinical process, with over 1.4 billion completed yearly in the USA. However, clinicians neglect with no 40 percent of patients with no veins, veins as well as 60 percent of patients in 27 percent of patients, according to research.


Repeated failures might require targeting veins at far greater cost and danger, and raise the probability of thrombosis, phlebitis and illnesses. Consequently, venipuncture is one of the top causes of harm to clinicians and patients. Furthermore, process time can boost by around one hour, needs employees and prices over $ 4 billion annually in the USA, based on estimates.


The apparatus might be utilized because IV catheterization, central venous access, dialysis and putting arterial lines in these processes. Next steps include optimizing the device to boost success rates in patients with veins that are difficult to get. Data from this analysis will be employed to boost artificial intelligence from the robot to boost its performance.


The analysis was led to by A researcher in Icahn School of Medicine at Mount Sinai Hospital.